Table 2.
Adverse events, causes of death and support treatment during hospitalization.
| Total (n = 609) | Alive (n = 481) | Deceased (n = 128) | p | |
|---|---|---|---|---|
| In-hospital adverse events | ||||
| Pneumonia | ||||
| Bilateral | 82.1% (499/608) | 79.4% (382/481) | 92.1% (117/127) | 0.000 |
| Unilateral | 10.4% (63/608) | 12.3% (59/481) | 3.1% (4/127) | 0.002 |
| Acute Respiratory failure | 79.1% (482/609) | 74.4% (358/481) | 96.9% (124/128) | 0.000 |
| MAS | 33.8% (206/609) | 32.2% (155/481) | 39.8% (51/128) | 0.105 |
| ARDS | 33.5% (107/609) | 47.5% (97/481) | 83.6% (107/128) | 0.000 |
| Acute Kidney Injury | 20.9% (127/609) | 13.9% (67/481) | 46.9% (60/128) | 0.000 |
| Acute Heart failure | 9.2% (56/609) | 7.3% (35/481) | 16.4% (21/128) | 0.001 |
| Sepsis | 6.9% (42/609) | 1.7% (8/481) | 26.6% (34/128) | 0.000 |
| Bleeding events | 4.1% (25/609) | 4.0% (19/481) | 4.7% (6/128) | 0.709 |
| Embolic events | 2.8% (17/609) | 2.1% (10/481) | 5.5% (7/128) | … |
| Cause of death | ||||
| ARDS | 67.97% (87/128) | |||
| Sepsis | 23.44% (30/128) | |||
| Suddden death | 3.12% (4/128) | |||
| Pulmonary embolism | 1.65% (2/128) | |||
| Other | 3.82% (5/128) | |||
| Support treatment | ||||
| Oxygen therapy | 85.2% (519/609) | 81.3% (391/481) | 100% (128/128) | 0.000 |
| High-flow oxygen therapy | 33.7% (205/609) | 19.3% (93/481) | 87.5% (112/128) | 0.000 |
| HFNC | 1.5% (9/609) | 0.6% (3/481) | 4.7% (6/128) | … |
| NIV | 2.1% (13/609) | 0.8% (4/481) | 7.0% (9/128) | … |
| IMV | 4.3% (26/609) | 0.8% (4/481) | 17.2% (22/128) | 0.000 |
| Prone ventilation | 15.6% (95/609) | 11.9% (57/481) | 9.4% (38/128) | 0.000 |
| Hydroxychloroquine | 90.8% (553/609) | 93.8% (451/481) | 79.7% (102/128) | 0.000 |
| Azithromycin | 83.3% (507/609) | 86.7% (417/481) | 70.3% (90/128) | 0.000 |
| Other antibiotics | 80.6% (491/609) | 78.0% (375/481) | 90.6% (116/128) | 0.001 |
| Corticoids | 43.2% (263/609) | 38.9% (187/481) | 59.4% (76/128) | 0.000 |
| Lopinavir/ritonavir | 22.2% (135/609) | 19.5% (94/481) | 32.0% (41/128) | 0.003 |
| Tocilizumab | 2.8% (17/609) | 2.3% (11/481) | 4.7% (6/128) | … |
| ACEI/ARB | 8.5% (52/609) | 8.3% (40/481) | 9.4% (12/128) | 0.666 |
| Anticoagulation | ||||
| Prohylactic LMWH | 70.3% (428/609) | 74.2% (357/481) | 55.5% (71/128) | 0.000 |
| Intermediate LMWH | 6.2% (38/609) | 6.0% (29/481) | 7.0% (9/128) | 0.674 |
| Anticoagulant LMWH | 14.0% (85/609) | 10.6% (51/481) | 26.6% (34/128) | 0.000 |
| Vitamin K antagonists | 1.5% (9/609) | 0.6% (3/481) | 4.7% (6/128) | … |
| Direct oral anticoagulants | 0.8% (5/609) | 0.8% (4/481) | 0.7% (1/128) | … |
ARDS: acute respiratory distress syndrome. ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker. HFNC: high flow nasal cannula. LMWH: low molecular weight heparin. MAS: macrophage activation syndrome. NIV: non invasive ventilation.